MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/clinem/dgaa851

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2021

Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.

Broadwell Aaron, Chines Arkadi, Ebeling Peter R, Franek Edward, Huang Shuang, Smith Shawna, Kendler David, Messina Osvaldo, Miller Paul D

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

CONTEXT: The effects of long-term exposure to denosumab in individuals with renal insufficiency are unknown.

OBJECTIVE

This post hoc analysis evaluates the long-term safety and efficacy of denosumab in individuals with mild-to-moderate chronic kidney disease (CKD) (stages 2 and 3) using data from the pivotal phase 3, double-blind, 3-year FREEDOM (NCT00089791) and open-label, 7-year extension (NCT00523341) studies.

PARTICIPANTS AND

METHODS

Women age 60 to 90 years with a bone mineral density (BMD) T-score of less than -2.5 to greater than -4.0 at the total hip or lumbar spine were randomly assigned 1:1 to receive denosumab 60 mg subcutaneously every 6 months (long-term arm) or placebo (cross-over arm) in FREEDOM; eligible participants could enroll in the extension to receive denosumab 60 mg subcutaneously every 6 months. Change in estimated glomerular filtration rate (eGFR) from study baseline and annualized rates of fracture and adverse events (AEs) were the main outcome measures.

RESULTS

Most participants (1259/1969 [64%] long-term arm; 1173/1781 [66%] crossover arm) with baseline CKD stage 2 or 3 remained within the same CKD subgroup at study completion; less than 3% progressed to CKD stage 4. Participants in all eGFR subgroups showed similar, persistent BMD gains over time and a low incidence of fractures. The percentage of participants reporting serious AEs was similar among renal subgroups (normal, CKD stage 2, CKD stage 3a, CKD stage 3b) both for the long-term (54% vs 52% vs 57% vs 58%) and crossover (43% vs 42% vs 43% vs 68%) arms, except CKD stage 3b subgroup, crossover arm.

CONCLUSION

The safety and efficacy of denosumab did not differ among participants with mild to moderate CKD.

Для цитирования: Broadwell Aaron, Chines Arkadi, Ebeling Peter R, Franek Edward, Huang Shuang, Smith Shawna, Kendler David, Messina Osvaldo, Miller Paul D. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.. The Journal of clinical endocrinology and metabolism. 2021. DOI: 10.1210/clinem/dgaa851.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.